Affiliation:
1. Department of Cardiac Surgery Boston Children's Hospital Boston MA 02115 USA
2. Department of Surgery Harvard Medical School Boston MA 02115 USA
3. Department of Lymphoma and Myeloma The University of Texas M. D. Anderson Cancer Center Houston TX 77030 USA
4. Harvard Stem Cell Institute Harvard University Cambridge MA 02138 USA
Abstract
AbstractCell transplantation success for myocardial infarction (MI) treatment is often hindered by low engraftment due to washout effects during myocardial contraction. A clinically viable biomaterial that enhances cell retention can optimize intramyocardial cell delivery. In this study, a therapeutic cell delivery method is developed for MI treatment utilizing a photocrosslinkable gelatin methacryloyl (GelMA) hydrogel. Human vascular progenitor cells, capable of forming functional vasculatures upon transplantation, are combined with an in situ photopolymerization approach and injected into the infarcted zones of mouse hearts. This strategy substantially improves acute cell retention and promotes long‐term post‐MI cardiac healing, including stabilized cardiac functions, preserved viable myocardium, and reduced cardiac fibrosis. Additionally, engrafted vascular cells polarize recruited bone marrow‐derived neutrophils toward a non‐inflammatory phenotype via transforming growth factor beta (TGFβ) signaling, fostering a pro‐regenerative microenvironment. Neutrophil depletion negates the therapeutic benefits generated by cell delivery in ischemic hearts, highlighting the essential role of non‐inflammatory, pro‐regenerative neutrophils in cardiac remodeling. In conclusion, this GelMA hydrogel‐based intramyocardial vascular cell delivery approach holds promise for enhancing the treatment of acute myocardial infarction.
Funder
National Institutes of Health
Subject
Pharmaceutical Science,Biomedical Engineering,Biomaterials
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献